Top Stories
Angelini Pharma agrees to acquire Catalyst Pharmaceuticals for $4.1 billion, establishing first US rare disease commercial platform
Italian pharma company Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $4.1 billion in cash, or $31.50 per share — a 28% premium to Catalyst's 30-day volume-weighted average price as of April 22, 2026 — in a deal that establishes Angelini's first meaningful US commercial footprint in rare disease, according to BioSpace's coverage of the announcement. The transaction, also covered by BioPharma Dive, transfers ownership of Catalyst's three commercial assets to Angelini: Firdapse (amifampridine) for Lambert-Eaton myasthenic syndrome (LEMS), Agamree (vamorolone) for Duchenne muscular dystrophy, and Fycompa (perampanel) for focal and primary generalized tonic-clonic seizures, US rights to which Catalyst acquired in 2023. The transaction has been unanimously approved by both companies' boards and is expected to close in Q3 2026, subject to customary regulatory and Catalyst shareholder approvals; Angelini plans to finance the acquisition with a combination of cash and debt with no financing contingency. The deal accelerates a broader pattern of European rare disease platforms entering the US through acquisition rather than organic build, and signals continued strategic value placed on rare neurology and neuromuscular assets with established commercial trajectories.
Taysha secures FDA alignment on TSHA-102 BLA pathway in Rett syndrome, with 6-month interim data as potential filing basis
Taysha Gene Therapies has reaffirmed regulatory alignment with the FDA on a BLA submission pathway for TSHA-102, its intrathecal AAV9 gene therapy for Rett syndrome, according to the company's Q1 2026 investor release. Following a recent breakthrough therapy Type B meeting, the FDA confirmed that 6-month interim data from the REVEAL pivotal trial could serve as the basis for a submission — a compressed timeline that, if realized, would mark one of the faster pivotal-to-filing sequences in CNS gene therapy. Taysha reported further patient dosing advances in REVEAL during Q1, with dosing completion in both REVEAL and the ASPIRE trial expected in Q2 2026 per the company's investor release. Rett syndrome affects an estimated 6,000 to 9,000 patients in the US, predominantly girls, with no currently approved gene therapy. The open question is whether 6-month functional data will carry sufficient durability signal to support accelerated approval, and what post-marketing commitments the FDA will require. Full trial topline data and confirmatory readouts remain key catalysts to watch.
Rocket Pharmaceuticals advances Danon disease program and earns KRESLADI accelerated approval, adding a PRV to its asset portfolio
Rocket Pharmaceuticals reported a series of program milestones in Q1 2026, anchored by FDA accelerated approval of KRESLADI and the receipt of a Rare Pediatric Disease Priority Review Voucher, according to the company's quarterly financial release. Simultaneously, the pivotal Phase 2 trial of RP-A501 for Danon disease — an X-linked lysosomal storage disorder affecting an estimated 3,000 to 5,000 patients in the US — has resumed dosing after a prior pause, a development that removes a near-term operational overhang on the program. The company also indicated first patient dosing in the Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy is anticipated for mid-2026, expanding Rocket's reach into rare cardiac indications. BioPharma Dive has tracked Rocket's cardiac gene therapy pipeline as one of the few programs targeting heritable cardiomyopathies with viral vector approaches. The PRV, which can be sold on the secondary market for an estimated $100 to $150 million based on recent transactions, provides a non-dilutive capital option. Danon disease pivotal data timing and RP-A701 Phase 1 enrollment pace are the primary near-term catalysts for portfolio watchers.
ELEVIDYS Q1 revenue of $102 million trails expectations, raising questions about gene therapy commercial uptake trajectory
Sarepta Therapeutics reported ELEVIDYS net product revenue of $102 million for Q1 2026, against total net product revenues of $330.5 million when combined with $228.6 million from its PMO franchise, according to Sarepta's Q1 2026 financial release. The ELEVIDYS figure fell short of analyst consensus, contributing to a notable stock decline as BioPharma Dive reported, with the gap raising questions about the pace of patient identification, payer access negotiations, and infusion center capacity constraints that have historically slowed one-time gene therapy uptake in the months following a broad label expansion. ELEVIDYS carries a list price of approximately $3.2 million per dose. The commercial dynamic observed here — where an approved, broadly labeled gene therapy underperforms revenue expectations in sequential quarters — has implications beyond Sarepta: it underscores the operational complexity of converting eligible patients into treated patients, particularly when reimbursement pathways involve outcomes-based contracts and prior authorization burdens. For the broader Duchenne market, the PMO franchise generating $228.6 million quarterly demonstrates that chronic small-molecule revenues remain the commercial backbone even as gene therapy adoption builds. Quarterly ELEVIDYS trends through H2 2026 will be a closely watched indicator of whether the trajectory inflects.
Pipeline Watch
The FDA issued an untitled letter to Alnylam over the consumer-facing Amvuttra website, alleging that open-label extension data were presented in a manner creating a misleading impression of the drug's efficacy profile, as Fierce Pharma reported. Amvuttra (vutrisiran) is approved for hereditary transthyretin-mediated amyloidosis with polyneuropathy. The letter does not constitute a warning letter but requires corrective action and signals FDA scrutiny of how RNAi therapy sponsors present real-world and open-label data in direct-to-patient communications.
RP-A701, Rocket Pharmaceuticals' AAV-based gene therapy for BAG3-related dilated cardiomyopathy, is expected to enter Phase 1 clinical dosing by mid-2026, per Rocket's Q1 2026 corporate update. BAG3-related DCM is a rare inherited cause of heart failure affecting an estimated 1,000 to 2,000 patients in the US. The program represents Rocket's second cardiac gene therapy in active clinical development alongside the Danon disease program.
CRISPR Therapeutics will present at the Bank of America Securities 2026 Global Healthcare Conference, while Intellia Therapeutics is participating in upcoming investor conferences, as each company's IR release confirmed. Both in vivo and ex vivo CRISPR programs are at various clinical stages. Investor presentations from both companies may provide updated clinical or regulatory timelines for their respective pipeline programs in hemoglobinopathies, TTR amyloidosis, and other rare targets.
A National Cancer Institute-sponsored trial evaluating stem cell transplantation for patients with germline RUNX1 mutations and associated hematologic neoplasms has been registered at ClinicalTrials.gov with a not-yet-recruiting status. Germline RUNX1 variants cause a rare inherited platelet disorder with leukemia predisposition, affecting a small but defined patient subset. The trial's opening will contribute evidence on the role of transplant versus emerging gene therapy approaches in RUNX1-driven disease.
Competitive Landscape
With ELEVIDYS generating $102 million against the PMO franchise at $228.6 million in a single quarter, the data suggest that even a fully approved, broadly labeled gene therapy at $3.2 million per dose displaces chronic therapy revenue slowly. Access complexity, not clinical differentiation, appears to be the primary rate-limiting variable in the near term.
| Product | Modality | Q1 2026 Revenue | Price Basis |
|---|---|---|---|
| ELEVIDYS | AAV Gene Therapy | $102M | $3.2M one-time |
| Sarepta PMO Portfolio | Exon Skipping (PMO) | $228.6M | ~$300K-500K/yr |
| TSHA-102 (Taysha) | AAV9 Gene Therapy | Pre-revenue | TBD |
| RP-A501 (Rocket) | AAV Gene Therapy | Pre-revenue | TBD |
The FDA untitled letter to Alnylam over Amvuttra website content creates a reference point for how open-label extension data may and may not be characterized in direct-to-consumer materials for rare disease RNAi therapies. Other RNAi sponsors with commercial products — including Alnylam's own broader portfolio and competitors in TTR amyloidosis — should review promotional practices against this standard.
Rocket Pharmaceuticals operates two active cardiac gene therapy clinical programs — RP-A501 in Danon disease at pivotal stage and RP-A701 in BAG3-related DCM entering Phase 1 — in a field where few other sponsors have reached human dosing in heritable cardiomyopathies. Patient populations are small but cardiac endpoints may support accelerated approval pathways similar to KRESLADI.
Forward Looking
- The Angelini-Catalyst transaction is expected to close in Q3 2026, subject to Catalyst shareholder approval and customary regulatory clearances; closing dynamics and integration plans for Firdapse, Agamree, and Fycompa will be the near-term watchpoints.
- With dosing completion in Taysha's REVEAL and ASPIRE pivotal trials targeted for Q2 2026, the 6-month interim REVEAL readout would be expected in late 2026; FDA acceptance of that data package as a BLA filing basis will be a key regulatory signal for the CNS gene therapy sector.
- Consecutive quarters of ELEVIDYS revenue below analyst expectations may accelerate payer and manufacturer negotiations around outcomes-based payment models for high-cost one-time gene therapies in Duchenne; H2 2026 quarterly trends will be the indicator.
- Rocket Pharmaceuticals' Rare Pediatric Disease PRV, estimated at $100 to $150 million in secondary market value, represents a potential non-dilutive capital event worth monitoring for transaction timing.